-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Reiterates Buy on Bioage Labs, Maintains $25 Price Target

Benzinga·09/09/2026 17:45:53
语音播报
Roth Capital analyst Adam Walsh reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $25 price target.